Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial
用户qp_rRVG66gHo
1个月前
87
10
已完结
1. 系统已在2025-09-10 09:54:54对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
R Lafayette, J Tumlin, R Fenoglio…
Journal of the …, 2024
journals.lww.com
Background The complement system plays a central role in the pathogenesis of IgA nephropathy. We present findings from a phase 2 trial of ravulizumab, a complement C5 …
